Melorheostosis is a sporadic disease of uncertain etiology characterized by asymmetric bone overgrowth and functional impairment. Using whole exome sequencing, we identify somatic mosaic MAP2K1 mutations in affected, but not unaffected, bone of eight unrelated patients with melorheostosis. The activating mutations (Q56P, K57E and K57N) cluster tightly in the MEK1 negative regulatory domain. Affected bone displays a mosaic pattern of increased p-ERK1/2 in osteoblast immunohistochemistry. Osteoblasts cultured from affected bone comprise two populations with distinct p-ERK1/2 levels by flow cytometry, enhanced ERK1/2 activation, and increased cell proliferation. However, these MAP2K1 mutations inhibit BMP2-mediated osteoblast mineralization and differentiation in vitro, underlying the markedly increased osteoid detected in affected bone histology. Mosaicism is also detected in the skin overlying bone lesions in four of five patients tested. Our data show that the MAP2K1 oncogene is important in human bone formation and implicate MEK1 inhibition as a potential treatment avenue for melorheostosis.
Melorheostosis (OMIM%155950) is a rare dysostosis characterized by excess bone formation in the classic “dripping candle wax” pattern on the surface of bone, revealed radiographically (Fig. 1a, b and Supplementary Fig. 1)1. The disease occurs in males and females equally, without familial clustering, and often affects multiple contiguous bones unilaterally in an asymmetric distribution2. Symptoms of melorheostosis may begin in childhood; the diagnosis is usually apparent by the age of 20 years3. The bone overgrowth lesions are associated with pain, functional impairment, joint contracture, and deformity. There is a wide spectrum of clinical appearance2 with skin lesions overlying the affected bone noted in up to 30% of patients. Bone lesions do not metastasize, but conversion to osteosarcoma has rarely been reported4. Increased uptake on bone scintigraphy suggests that melorheostotic bone is metabolically active (Fig. 1c–e). Patients are diagnosed by a combination of clinical findings, radiographs and bone scan. There is no definitive diagnostic test or specific treatment for melorheostosis2.
At present, two patterns of occurrence of melorheostosis have been differentiated by genetics. Patients with the autosomal dominant “spotted bone disease” osteopoikilosis and the related condition Buschke–Ollendorff syndrome (OMIM #166700) may display features of melorheostosis, and have been shown to have germline loss-of-function mutations in LEMD3, encoding the inner nuclear membrane protein MAN15. LEMD3 mutations have not been found in patients with the more common sporadic melorheostosis without osteopoikilosis6; the genetic cause of their condition is undefined7. Recently, a patient with melorheostosis and familial osteopoikilosis was found to have a germline LEMD3 mutation and a somatic KRAS mutation in an overlying area of scleroderma-like skin8. Whether the KRAS mutation was causative for the bone findings in this one patient remains undetermined. The lack of vertical genetic transmission and asymmetric involvement suggests that sporadic melorheostosis may be caused by somatic mutations in bone-forming cells9, but bone tissue has not been previously investigated for somatic mutations in bone forming cells.
We biopsied affected and unaffected bone of 15 patients with melorheostosis and compared the tissue whole exome sequences for each patient. We identified mutations in the MAP2K1 gene in affected, but not unaffected, bone of eight patients. MAP2K1 encodes the protein MEK1, a kinase whose activity is modulated by its negative regulatory domain. The MAP2K1 mutations identified in melorheostosis patients cause substitutions in two residues of the MEK1 negative regulatory domain. We present genetic, functional and histological data supporting the enhancement of MEK1 activity predicted by the location of the mutations and the causative role of the MAP2K1 mutations in melorheostosis. This study provides evidence of a bone disease caused by mutations in MAP2K1.
Identification of mosaicism for MAP2K1
Fifteen patients with melorheostosis underwent biopsies of affected and unaffected bone (Supplementary Table 1 and 2). A consistent intraoperative finding was extremely dense, rigid affected bone that often dulled the osteotomes and drill bits. Genomic DNA was extracted from both tissues and subjected to high-depth whole exome sequencing. We identified 8365 sequence variants that were present in a subject’s affected bone but not unaffected bone. After restricting these variants to those that were found in more than 1% of sequences (but less than germline frequency), rare in the general population, and predicted to alter protein coding or mRNA splicing, we were left with 284 variants (Fig. 2a and Table 1). Only five genes contained putative somatic mutations in more than one affected bone sample (MAP2K1, USH2A, CCDC13, SIRT5 and RAB44). Among these five genes, it was striking that sequences from five affected bone samples contained one of three tightly clustered missense mutations in the coding region of MAP2K1, c.167 A > C (p.Q56P), c.169 A > G (p.K57E), and c.171 G > T (p.K57N), encoding substitutions in two adjacent amino acids of the protein MEK1 (Fig. 2b and Supplementary Data 1). These coding variants are not present in the exomes of 123,136 healthy individuals searchable with the ExAC10. Both substituted residues are located in a MEK1 α-helix that negatively regulates kinase function (Fig. 2b and Supplementary Fig. 2)11. All three of these mutations have been previously shown to lead to gain-of-function through loss of the inhibitory role of the negative regulatory domain and have been identified in malignancies, including lung12, melanoma13 and hairy cell leukemia14 (Supplementary Table 3). All other 281 variants were unique to the affected bone of 1 of the 15 subjects (Supplementary Data 1). No germline or somatic LEMD3, MAP2K2 or MAP2K3 variants were identified in automated or manual re-examination of exome sequencing data from any patient. A KRAS p.Q61R mutation was found in both the affected and unaffected bone of one MAP2K1 mutation-negative patient with skin lesions consistent with RASopathy, who likely has melorheostosis as part of a more complex early embryonic mosaic RASopathy, which will be reported separately. Thus 5 of 15 patients were identified to have MAP2K1 mutations by whole exome sequencing.
The allele frequency of these somatic heterozygous MAP2K1 mutations identified by automated somatic mutation calling was relatively high (10–25%). We performed amplicon-based targeted sequencing to validate the exome sequencing findings and screen the remaining patients for MAP2K1 mutations at higher sensitivity. This approach revealed three additional patients with MAP2K1 p.K57N mutations at lower mutant allele frequencies (Table 1). Amplicon-seq polymerase errors were less than 1% at the base positions in question (Supplementary Tables 4, 5 and 6). Their mutations were missed by WES due to low allele frequencies in patients Melo-16 and Melo-6 (2.7% and 4.8%, respectively) or low coverage in patient Melo-2 (58×). All eight MAP2K1 mutations were then confirmed by droplet digital PCR (ddPCR) of DNA from affected bone (Fig. 2c). The MAP2K1 mutant allele frequency in affected bone by ddPCR ranged from 9 to 28% for p.Q56P, 3–34% for p.K57N, and 18% for p.K57E and correlates well with amplicon and WES data.
The ddPCR mutant allele frequency in osteoblasts cultured from melorheostotic bone of seven subjects, varied from 0.05 to 47% and was similar in different samples from the same cell culture, but often did not match the frequency found in bone tissue, consistent with tissue mosaicism. For example, there was a markedly higher frequency of the p.K57N mutation in cultured osteoblasts than bone tissue from patient Melo-2 (40–47% in cell passages 1–5 vs. 6.9% in bone) and a lower frequency of p.Q56P in Melo-4 (0.05–0.2% in cell passages 1–5 vs. 10% in bone tissue).
Mosaicism for their respective MAP2K1 mutations was also detected in skin tissue overlying affected bone of patients Melo-2, Melo-4, Melo-6 and Melo-18, but not detected in skin from patient Melo-16, who has a lower disease burden. To look for germline mutations, we tested blood samples available from seven patients. MAP2K1 mutations were not identified in blood samples including those with mutation-positive skin tissue, further confirming mosaicism (Table 1).
Melorheostosis histology reveals intense remodeling
To gain insights into the effects of MAP2K1 mutations on bone structure, remodeling and mineralization, we compared histomorphometry of tissue sections from affected and unaffected bone in six patients. Melorheostotic bone was characterized in the outer regions by distinctive parallel layers of primary lamellar bone, an organization that underlies the surgical hardness of the bone (Fig. 3a). This newly formed compact tissue was intensely remodeled into a highly porous osteonal-like bone at greater depth from the surface (Fig. 3b). Compared to unaffected bone, affected bone showed increased active bone-resorbing osteoclasts, elevated eroded surfaces and a higher number of bone-forming osteoblasts (Fig. 3c). There was an approximately six-fold increase in the thickness of osteoid (unmineralized bone matrix) and a greater than 50-fold increase in osteoid surface/bone surface in the affected bone samples compared to their respective unaffected counterparts (Fig. 3c, d).
MEK1 signaling increased in melorheostosis
To determine how the MAP2K1 mutations identified in our cohort affected the MEK1 target kinases ERK1 and ERK2, we examined MEK1 activity by immunohistochemical analysis of phosphorylated ERK1/2 (p-ERK1/2) in sections of affected bone tissue from two patients with MAP2K1 mutations. Osteocytes and osteoblasts in affected bone displayed stronger p-ERK1/2 signals than control bone, but no p-ERK1/2 signal was detected in osteoclasts (Fig. 4a). Consistent with somatic mosaicism, the p-ERK1/2 positive cells occurred in patches in affected bone tissue.
Furthermore, osteoblasts cultured from affected bone and having a high frequency of mutant MAP2K1 cells (approximately 80%) exhibited a bimodal ERK1/2 activation after serum-stimulation when examined by flow cytometry for intracellular p-ERK1/2. Bimodal ERK1/2 activation was not observed in cells from unaffected bone. Both peaks of ERK1/2 activation in osteoblasts from affected bone, likely representing wild-type and mutant cells, were reduced by the MEK-specific inhibitor U0126. Baseline p-ERK1/2 was also higher in a proportion of affected cells than in unaffected cells (Fig. 4b). These findings would be expected from a mixed cell population and confirm MAP2K1 mosaicism at the cellular level.
We also investigated the MEK1-ERK1/2 pathway in cultured osteoblasts harboring MAP2K1 mutations by western blot analysis in seven patients (Fig. 4c). Osteoblasts from the same patient and passage as those analyzed by flow cytometry showed increased p-ERK1/2 compared to cells from unaffected bone, indicating MEK1 gain-of-function (Supplementary Fig. 4). FBS-induced ERK1/2 activation could more readily be seen in unaffected osteoblasts by western blotting, likely due to the increased sensitivity in comparison to flow cytometry. Pre-treatment of cells with U0126 significantly diminished serum-stimulated p-ERK1/2, supporting enhanced MEK1 activity as mediating the increased ERK1/2 activation. The level of ERK1/2 activation by MEK1 generally correlated with mutant allele frequency. Activation was clearly seen in Melo-2 and Melo-18, with the highest percentage of mutant cells. In cells cultured from affected bone of Melo-10 with lower mutant allele frequency of 10%, the activation of ERK1/2 by MEK1 was equivocal (Supplementary Fig. 4).
MEK1 activation increases cell proliferation
MAP2K1 mutations did not affect MAP2K1 transcripts (Fig. 5a) or MEK1 protein levels (Fig. 5b), supporting a gain-of-function mechanism intrinsic to the protein itself. ERK1/2 activation promotes G1 to S-phase cell cycle progression and accelerates cell proliferation. The enhanced MEK1-ERK1/2 activation in affected osteoblasts increased cell proliferation in vitro (Fig. 5c). For example, the doubling time of osteoblasts from affected bone of patient Melo-2 (mutant allele frequency 45%) was 18 h, while osteoblasts from this patient’s unaffected bone had a doubling time of 54 h. Osteoblasts from affected bone did not lose contact inhibition. Furthermore, affected osteoblasts showed increased levels of cyclin D3 expression compared to unaffected cells, consistent with accelerated G1-S cell cycle transition (Fig. 5d).
MEK1 activation decreases osteoblast differentiation in vitro
To further investigate the functional consequences of the MAP2K1 mutations causing melorheostosis, osteoblast differentiation and mineralization were assessed in vitro. The presence of the MAP2K1 mutation strikingly inhibited BMP2-stimulated mineralization in affected compared to unaffected osteoblasts (Fig. 5e). Expression of marker genes for osteoblast differentiation was also reduced in cells with the MAP2K1 mutation during BMP2-stimulated differentiation (Fig. 5f). Reduced expression of RUNX2 (runt-related transcription factor 2), ALPL(alkaline phosphatase) and COL1A1 (the α1 chain of type I collagen) indicates the prevalence of immature bone forming cells. Osteoblasts early in differentiation secrete proteins to stimulate osteoclastogenesis15. In fact, we observed a markedly increased ratio of RANKL/OPG transcripts in osteoblasts from affected bone, which would generate a strongly positive context for osteoclastogenic stimulus (Fig. 5f)16.
Together, these data support key histological findings in affected bone. Inhibition of mineralization by overactive MEK1 accounts for the massive accumulation of unmineralized osteoid in affected bone tissue (Fig. 3d). Furthermore, the elevated RANKL/OPG ratio stimulates the increased osteoclast number and intense remodeling that occurs in melorheostotic bone (Fig. 3c).
Genetic osteosclerotic disorders are a rare but interesting subset of bone diseases which can provide important insights into bone biology. Identification of a germline mutation causing sclerosteosis led to the development of a potential treatment for osteoporosis17,18,19. Investigations into fibrodysplasia ossificans progressiva elucidated the role of inflammation in heterotopic ossification and exposed targets for treatment20. Here, our investigation has revealed a role for MEK1 in a disorder characterized by excessive bone formation.
We identified mutations in MAP2K1 in the affected, but not unaffected, bone of 8 of 15 patients diagnosed clinically and radiologically with melorheostosis. The mutations cluster at two residues in the MEK1 negative regulatory domain, p.Q56 and p.K57, where identical substitutions have been identified in multiple malignancies, but not primary bone tumors. The occurrence of the mutations in a MEK1 “hot spot,” and the evidence of enhanced MEK1-ERK1/2 signaling in melorheostotic bone and osteoblasts, strongly support MAP2K1 somatic mutations as causing about half of cases of sporadic melorheostosis. In our cohort, we found no occurrences of somatic or germline mutations in LEMD3, which have previously been reported in patients with familial osteopoikilosis and features of melorheostosis6, 8.
Mosaicism for cells with increased ERK1/2 activation was confirmed directly in melorheostotic bone by immunohistochemistry. Furthermore, two populations of cells with distinct levels of ERK1/2 activation were detected by flow cytometry. Increased ERK1/2 activation was also detected in cultured osteoblasts from affected, but not unaffected bone. In individual patients, the proportion of cultured mutant osteoblasts often differed from the proportion of mutant allele in genomic DNA extracted from bone chips from the same lesion, consistent with clustering of affected cells in mosaic conditions.
The three MAP2K1 mutations we identified in melorheostosis have been shown to increase MEK1 activity in transfection studies21, and likely act by destabilizing the α-helix comprising the MEK1 negative regulatory region, which normally keeps the ATP-binding site in an inactive conformation11. MEK1 is a downstream activator in the RAS pathway. Mutations in RAS pathway components are associated with developmental defects falling under the umbrella designation RASopathies22 and involve variable cardiac, facial and neurodevelopmental defects. Interestingly, germline mutations identified in leukocytes from patients with the RASopathy cardio-facio-cutaneous syndrome23, 24 include two MAP2K1 mutations (p.G128V/p.Y130C) in the catalytic core, and putatively activating mutations in the negative regulatory region of MAP2K1 (p.F53S) or MAP2K2 (p.F57V, analogous to MAP2K1 p.F53). Bone overgrowth is not reported in these RAS-MAPK syndromes, implying that the somatic mutations we report in osteoblasts produce a different phenotype than the same mutation in the germline. Mosaicism for mutations at the same residues (p.Q56P and p.K57E) we identified in the MEK1 negative regulatory domain in melorheostosis patients has recently been reported in endothelial, but not skin or blood, cells of patients with extracranial arteriovenous malformations (AVM)25. Similar to melorheostotic bone lesions, AVM lesions caused by MAP2K1 mutations expand but do not metastasize.
While the MAPK pathway is known to be involved in skeletogenesis and MEK1 is essential in embryogenesis, our study documents the importance of the MEK1-ERK1/2 pathway in human bone cell biology. While somatic mutations in MAP2K1 have also been reported in Langerhans cell histiocytosis and Erdheim–Chester disease (ECD)26, the mutated cells in ECD are derived from monocytes rather than osteoblasts. Bone lesions in ECD are typically bilateral and symmetrical and occur in trabecular bone of the epiphysis27. In contrast, activation of ERK1/2 MAP kinases in melorheostosis occurs in osteoblast lineage and the lesions are primarily cortical.
Transgenic murine models, in which the entire MEK1 negative regulatory domain was deleted, share the elevated ERK1/2 signaling seen in melorheostosis28. However, the mice displayed accelerated bone remodeling rather than bone overgrowth. The mouse osteoblasts also showed increased differentiation and mineralization, but unchanged proliferation in vitro.
In melorheostosis, activation of the MEK1-ERK1/2 pathway in mature bone results in an increase in osteoblast surface and increased production of unmineralized bone matrix (osteoid). This is consistent with the faster proliferation of osteoblasts cultured from melorheostotic bone and with the less differentiated osteoblast phenotype revealed in vitro in BMP2-stimulated cells, in which transcripts of osteogenic genes RUNX2, COL1A1, and ALPL were decreased. Histologically, we observed a significant increase in osteoid formation and osteoclast numbers in affected bone from the MAP2K1 variant cohort. Interestingly, these features were previously noted in a single case report29 with unknown genetics. The increased osteoid seen in vivo is consistent with the decreased mineralization deposited by affected osteoblasts in vitro with BMP2 stimulation. Increased osteoclast numbers and bone turnover in affected bone is consistent with the increased RANKL secretion by cultured cells, which would stimulate osteoclast development and intense bone remodeling. Furthermore, it is known that chronic activation of ERK1/2 strongly inhibits BMP2-mediated mineralization, as previously shown in a murine model for neurofibromatosis30, and provides an underlying mechanism for the increased unmineralized osteoid found in melorheostotic bone. The phenotypic distinction between murine models and melorheostosis patients may be ascribed to overexpression of the MEK1 transgene in all murine osteoblasts as opposed to the mosaic mutations in melorheostosis, or greater disruption of function by deletion of the full negative regulatory domain28, 31. Furthermore, studies in fruit flies and zebrafish indicate that activating MAP2K1 mutations affect ERK1/2 activation differently depending on pathways intrinsic to the target tissue and developmental state22.
Identification of a somatic mosaic mutation in osteoblasts accounts for the unique clinical features of melorheostosis. The “dripping candle wax” pattern observed on radiographs is due to marked appositional bone growth followed by aggressive remodeling. The radiographic pattern of multiple contiguous bones affected while others are spared may be due to longitudinal expansion of mutant osteoblasts precursors along the axis of development (Supplementary Fig. 5)32. The marked variability in the pattern of bone lesions between patients is likely related to mutations arising during different points during development, with earlier mutations resulting in an increased burden of disease. Further studies will delineate the roles of specific MAP2K1 mutations in different tissues at various developmental stages.
Melorheostosis can now be viewed as a genetically heterogeneous group of dysostoses. The melorheostosis seen in patients who have “spotted bone” osteopoikilosis is associated with a mutation in germline LEMD36. Whyte et al. have shown that additional somatic mutations in KRAS (and possibly other genes) may play a role in the development of “dripping candle wax” bone lesions on radiographs in some patients in an osteopoikilosis kindred8. Patients who have sporadic melorheostosis are a distinct group and do not have germline6, 33, or as we now show, somatic mutations in LEMD3. It remains to be seen if the radiographic similarities in melorheostosis caused by LEMD3 mutations and MAP2K1 mutations are due to involvement of a common pathway with activation of SMADs, or are simply a similar clinical outcome.
Our finding that three of four patients demonstrated mutations in the overlying skin raises the possibility that testing of skin for MAP2K1 mutations may be a diagnostic test for melorheostosis. However, if the skin sample is negative, bone biopsy may still be necessary to detect the mutation, especially in patients with a low mutant allele frequency. Although the causative gene is an oncogene, the clinical data from many years is reassuring to patients that malignant degeneration is rare2, 4.
Development of a diagnostic test is especially valuable because identification of somatic MAP2K1 mutations in melorheostosis raises the possibility of inhibiting MEK1 to treat melorheostotic bone lesions. Several MEK1 inhibitors have already been developed for malignancies with MAP2K1 mutations identical to those we identified in melorheostosis34. Because melorheostosis is one of few osteosclerotic bone-forming diseases, study of the MEK1-ERK1/2 pathway may lead to insights relevant to diseases where bone formation is impaired, such as delayed fracture healing and osteoporosis.
Patient cohort and bone sampling
We recruited 20 unrelated adults with a diagnosis of melorheostosis to a NIAMS Institutional Review Board-approved protocol (NCT02504879). Diagnoses were confirmed by radiographs and increased uptake on 18F-NaF bone scan (Fig. 1). Patients were excluded if pregnant or lactating, if under the age of 18, if actively infected or if unable to provide informed consent. Study subjects were not compensated for their participation. Fifteen patients consented to bone biopsies of affected and contralateral unaffected bone (see Supplementary Table 1 for clinical characteristics). Patients consented to publication of photographs.
Patients underwent open surgical biopsy of the affected bone under fluoroscopic guidance. The site of the biopsy of affected bone was chosen to minimize risk. Thus the most superficial area of melorheostotic bone was chosen. Under general anesthesia, the limb was exsanguinated and a tourniquet elevated (in all but one patient with proximal femur lesion). The bone was exposed and any thickened periosteum divided. Fluoroscopy was used to confirm the site of affected bone. Four drill holes were used to create a rectangle, and an osteotome used to connect the drill holes. The rectangular piece of cortical bone was then removed and sectioned in the operating room. The sections were placed immediately in cell culture media (for DNA extraction and osteoblast culture) or 70% ethanol for histology. Hemostasis was obtained with electrocautery and the wound closed in layers. A contralateral control sample of bone with no radiographic evidence of melorheostosis was also obtained.
For some patients, such as Melo-2 and Melo-18, abundant melorheostotic bone was available for evaluation. For other patients, only a small amount of affected bone could be safely sampled; priority was given to bone for DNA extraction followed by osteoblast culture over other studies. In all patients, the smallest informative sample of normal bone was taken to minimize morbidity. Thus, normal bone was often a limiting reagent. See Supplementary Table 2 for details on which patient samples underwent particular experiments.
Additional tissue sampling
In our initial study design, we were concerned that surgical biopsy of melorheostosis (which had never been done before) could lead to worsening of the disease, infection, or other complication. Therefore, only the smallest amount of usable bone was collected. After a shared mutation was identified and the absence of surgical complications assured, four patients returning for a follow-up visit underwent 6 mm punch biopsy of skin overlying an area of affected bone, and a control biopsy of unaffected skin from the contralateral side. Seven of the eight patients with MAP2K1 mutations agreed to have blood tested for mutations. DNA from peripheral blood leukocytes was tested by ddPCR for presence of the mutation.
Genomic DNA extraction and mutation detection in bone tissue
Soft tissues and cartilage were manually dissected from affected and unaffected bone of each patient. Following repeated washes in phosphate-buffered saline (PBS) containing no Ca2+ or Mg2+ to remove marrow, mineralized tissues were minced using a rongeur and spring scissors in a sterile conical bottom glass tube (Roboz, Gaithersburg, MD).
Genomic DNA was isolated from minced bone chips following the manufacturer’s instructions (Gentra Puregene, Qiagen). In brief, minced bone samples were resuspended in cell lysis solution and digested with 0.2 mg/ml proteinase K at 55 °C for 12 h. Digested proteins were precipitated and removed by centrifugation at 14,000×g for 3 min. The cleared supernatant was transferred to a new tube and genomic DNA was precipitated with isopropanol and collected by centrifugation at 14,000×g for 5 min. The DNA pellet was washed once with 70% ethanol and air-dried at room temperature for 5 min. DNA was resuspended in DNA hydration buffer (10 mM Tris, 1 mM EDTA, pH 8.0) and its concentration was measured using a NanoDrop spectrophotometer (ThermoFischer Scientific).Genomic DNA samples underwent deep Whole Exome Sequencing (Otogenetics), with 107–270× coverage for each sample. Most exome targets (82%) had at least 50× coverage in each sample. Agilent SureSelect Human 51 Mbp All Exon kit was used for exome capture. Paired-end sequencing was performed on Illumina HiSeq sequencers. Sequencing reads were returned in FASTQ format and were aligned to Human Reference Genome Build 37 using Burrows–Wheeler alignment Tool. The standard PICARD-GATK pipeline was used to remove duplicate reads, refine alignment around indels, and recalibrate base quality scores. The resulting BAM files (one per sample) served as inputs to somatic mutation callers (Fig. 2a).
Two somatic mutation callers (muTect v1.1.7 and Strelka v1.0.1435) were used, with default parameters for WES data. Somatic variants called by either method were annotated with functional impact and population frequency using ANNOVAR. We filtered somatic variants for those that were not present in the unaffected bone, caused protein or ncRNA sequence changes or splicing changes, had less than 1% frequency in ExAC and 1000 Genomes Project databases, were not in a duplicated genomic region, and were called by both muTect and Strelka. Using this method, 284 putative somatic variants were identified in 15 affected bone samples (Supplementary Data 1 and Supplementary Fig. 2).
Exome sequencing was complemented by high-coverage amplicon sequencing with an average sequencing coverage of more than 10,000 × per sample. A targeted NGS amplicon library prep kit from Swift Biosciences (56 G Oncology) was used to screen patients for MAP2K1 somatic mutations. The panel targets cancer-associated mutations in 56 genes including 5 mutation hotspot regions in MAP2K1 (exons 2, 3, 6, 7, 11), as well as the RAS codon 12, 13 and 61 hotspot mutations. The amplicon libraries were sequenced on Illumina MiSeq and variants were called with LoFreq 2.1.2.
To validate and quantitate the allele frequency of somatic mutations in other tissues and cells cultured ex vivo, we utilized ddPCR (Fig. 2c). The approach determines the abundance of each allele using allele-specific hydrolysis probes (Supplementary Table 7) complementary to mutant allele (FAM-labeled) and wild-type allele (HEX-labeled) and is based on partitioning of each sample into >10,000 nanoliter-sized droplets, in which PCR is carried out. gBlock oligos of 200 bp bearing the mutation of interest were designed by Integrated DNA Technologies, Inc. (Coralville, IA) and used as mutation-positive controls. Reactions were performed on the QX200 Droplet Digital PCR System (Bio-Rad), using standard PCR cycling conditions based on manufacturer’s instructions (10-min enzyme activation at 95 °C, followed by 40 cycles of 30-s 94 °C denaturation and 1-min 55 °C annealing/extension, finishing with a 10-min enzyme deactivation at 98 °C). QuantaSoft software was used to quantitate the concentration of each allele as the number of copies per microliter, using a Poisson distribution model to account for the number of target copies per individual droplet. Fractional abundance of mutant allele was calculated as the concentration (copies per microliter) obtained in FAM channel divided by sum of concentrations of FAM and HEX channels.
Bone histology and histomorphometry
Bone samples from a subset of 6 patients with MAP2K1 mutations were embedded in polymethylmethacrylate and prepared for histomorphometric analyses using standard procedures36. For histological examinations, thin sections (4 µm) were cut from the tissue blocks with a hard tissue microtome (Leica SM2500, Leica Microsystems Nußloch GmbH), deplasticized with 2-methoxyethyl-acetate and stained with modified Goldner’s Trichrome36 (Fig. 3d). A light microscope equipped with a video camera (Zeiss Axiophot, Zeiss AxioCam, Oberkochen, Germany) was used to obtain digital images of the sections that were analyzed using NIH ImageJ software (version 1.63)37. Bone histomorphometric analyses were performed on 4 randomly chosen areas throughout each bone section (Fig. 3c). Because bone samples from the various skeletal sites contained predominantly compact/osteonal bone, only indices of bone formation and resorption were evaluated: osteoid thickness (O.Th), osteoid surface per bone surface (OS/BS), osteoblast surface per bone surface (Ob.S/BS), osteoclast surface per bone surface (Oc.S/BS) and eroded surface per bone surface (ES/BS). Bone lamellar organization was observed under polarized light.
Subsequently, the residual blocks were prepared for backscattered electron imaging by grinding and polishing to obtain plane parallel surfaces, then carbon coated (Fig. 3a, b). The entire cross-sectioned bone sample area was imaged with a spatial resolution of 1.8 µm per pixel using a field emission scanning electron microscope (FESEM) (Zeiss Supra 40, Oberkochen, Germany) equipped with a four-quadrant semiconductor backscatter electron detector. The FESEM was operated with electron energy of 20 keV. The gray levels reflecting the mineral/calcium content were calibrated by the material contrast of pure carbon and aluminum.
Statistical evaluation was performed with GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). Comparison of histomorphometric indices were based on paired t-test comparing affected vs. unaffected tissue in each patient. Statistical significance was considered as p < 0.05.
Primary osteoblasts were grown from freshly minced bone chips according to the method of Robey and Termine38. Bone chips (~ 1 mm) were incubated in alpha-minimal essential medium (α-MEM, Life Technologies) containing type II collagenase (200 U/ml, Worthington Biochemical Corp., Lakewood, NJ) for 2 h at 37 °C with gentle rocking. Bone chips were allowed to settle briefly, then collagenase solution was removed and washed twice with PBS. Bone chips were placed in T75 tissue culture flasks with α-MEM supplemented with 10% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA) and antibiotics (penicillin (100 U/ml) and streptomycin (100 µg/ml), Thermo Fisher Scientific Inc.). Bone chips were incubated for 2–3 weeks at 37 °C/8% CO2, refreshing culture media every 3 days. Osteoblasts of passages 1–4 were used in this study.
Genomic DNA was extracted from cultured osteoblasts using the Gentra Puregene kit (Qiagen), as described above. The proportion of mutant MAP2K1 allele in DNA from multiple cell passages and revivals was determined by ddPCR as above.
Cell proliferation assay by live-cell imaging
Osteoblasts were plated at the indicated densities in 96-well tissue culture dish and imaged at 2 h intervals for 120 h using the IncuCyte ZOOM Kinetic Imaging System (Essen Bioscience) at 10× magnification (Fig. 5c). During the live-cell imaging, cells were incubated in 37 °C/8% CO2. Percent confluence was calculated from the percentage of the well area occupied by cells. Doubling time was calculated using GraphPad Prism 6.0 using non-linear regression. To analyze comparable populations of cells between groups, only wells with confluency at the first time-point of image acquisition within one half standard deviation of the mean were included in the analysis. Statistical comparison was done by two-way ANOVA.
Gene expression in osteoblasts by real-time quantitative PCR
Total RNA was extracted from osteoblasts using the RNeasy mini kit (Qiagen) following the manufacturer’s instruction. RNA concentration was measured by the NanoDrop spectrophotometer. Synthesis of cDNA was performed using 1 µg of total RNA and the High‐Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific), following the manufacturer’s instructions. Comparative real-time PCR was performed in triplicate with an Applied Biosystems Prism 7500 Fast Sequence Detection System using TaqMan universal PCR master mix, according to the manufacture’s protocol (Applied Biosystems Inc., Foster City, CA) (Fig. 5a, f, g). The TaqMan probes and primers were purchased from Applied Biosystems: Human RUNX2 (Hs01047973_m1), COL1A1 (Hs00164004_m1), ALPL (Hs01029144_m1), RANKL (TNFSF11, Hs00243522_m1), OPG (TNFRSF11B, Hs00900358_m1). Human GAPDH (Hs02786624_g1) and TBP (Hs00427620_m1) were used as endogenous controls for normalization. Levels of MAP2K1, RUNX2, ALPL and COL1A1, RANKL (TNFSF11), and OPG (TNFRSF11B) transcripts were determined using the 7500 Fast System SDS software version 1.3.1 (Applied Biosystems). Relative expression was calculated using the comparative ∆∆Ct method.
Flow cytometric analysis for intracellular p-ERK1/2
Osteoblasts cultured from affected and unaffected bone of melorheostosis patients were serum-starved for 1 h and stimulated with 20% FBS with or without MEK inhibitor U0126 (10 μM) for 30 min. Osteoblasts were then harvested for intracellular staining with antibodies for p-ERK1/2. After fixation with 4% paraformaldehyde and permeabilization with ice cold methanol, cells were washed in PBS containing 1% BSA. Cells were stained for 60 min in the dark at room temperature with the following antibodies (Cell Signaling Technology, Cambridge, MA): Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204), (197G2), (clone E10) rabbit monoclonal antibody (Alexa Fluor 647®Conjugate) (#13148) (1:100 dilution) or rabbit IgG isotype control (Alexa Fluor® 647 Conjugate) #3452). Cells were acquired on a FACSVerse™ flow cytometer (Becton Dickinson) and analyses for p-ERK1/2 levels were performed by using FlowJo® software (Tree Star) on live gated cells (Fig. 4b). The gating strategy is shown in Supplementary Figure 7.
Western blot analysis of MEK1 and ERK1/2 activation
Osteoblast lysates were analyzed by western blotting using standard methods and indicated antibodies (Fig. 4c, b, d). Briefly, osteoblasts from affected and unaffected bone of melorheostosis patients were grown in α-MEM supplemented with 10% FBS (Gemini Bio-Products, West Sacramento, CA) and antibiotics (penicillin (100 U/ml) and streptomycin (100 µg/ml), Thermo Fisher Scientific Inc.). Cells were seeded at 75,000 cells/well in 12-well tissue culture vessel containing 1 ml/well of culture media. On the next day, cells were pre-treated with U0126 (1, 4-diamino-2, 3-dicyano-1,4-bis[2-aminophenylthio] butadiene, a MEK1/2 inhibitor, for 1 h. Inhibitor concentration in culture was 10 µM (#9903, Cell Signaling Technology) or DMSO (vehicle control, Sigma) in serum-free α-MEM. Cells were then stimulated with FBS (20% in media) for 30 min before being lysed in cell lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% sodium disodium sulfate, 1× protease inhibitor cocktail, and 1× phosphatase inhibitor cocktail). Cell lysates were cleared by centrifugation at 20,000×g for 20 min at 4 °C. Soluble cell lysates were mixed with SDS-PAGE sample buffer (50 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.1% bromophenol blue, and 100 mM dithiothreitol) and denatured at 80 °C for 10 min. Proteins were resolved in 4–15% mini-PROTEAN precast gels (Bio-Rad, Hercules, CA) at 100 V for 90 min. The resolved proteins were transferred to nitrocellulose membranes (Bio-Rad) at 100 V for 90 min at 4 °C. The membranes were immersed in 5% bovine serum albumin in Tris-buffered saline containing 0.5% Tween-20 (TBS-T) for 1 h at room temperature to block non-specific binding of primary antibodies. Subsequently, the membranes were probed with the following antibodies (Cell Signaling Technology, Cambridge, MA): phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (clone #D13.14.4E) rabbit monoclonal antibody (#4370, 1:2000), p44/42 MAPK (Erk1/2) (clone # L34F12) mouse monoclonal antibody (#4696, 1:2000), MEK1/2 rabbit antibody (#9122, 1:1000), cyclin D3 (clone #DCS22) mouse monoclonal antibody (#2936, 1:2000), GAPDH (clone #D16H11) rabbit monoclonal antibody (#5174, 1:1000), and COX IV (clone # 3E11) rabbit monoclonal antibody (#4850, 1:1000). After incubating membranes with primary antibodies for 16 h at 4 °C, membranes were washed in TBS-T three times for 5 min each at room temperature. Protein bands were visualized by incubating membranes for 1 h at room temperature with the following secondary antibodies (LI-COR Biosciences, Lincoln, NE): IRDye® 680RD anti-rabbit IgG (#926-68071, 0.1 ug/ml) or IRDye® 800CW anti-mouse IgG (#926-32210, 0.1 ug/ml). The membranes were washed in TBS-T three times for 5 min each at room temperature before scanning with Odyssey® Infrared Imaging Systems (LI-COR Biosciences, Lincoln, NE). Uncropped western blots are available in Supplementary Figure 6.
Immunohistochemistry for p-ERK1/2
Fresh bone tissue was fixed in 10% neutral buffered formalin, decalcified by formic acid, and embedded in paraffin. Thin sections (5 µm) were mounted onto tape adhesive slides. Following deparaffinization and rehydration with ethanol, endogenous peroxidase was blocked using 3% hydrogen peroxide/distilled water. Antigen retrieval was performed using a citrate buffer (BioGenex) for 10 s at 100 °C, then slides were cooled and rinsed in distilled water and Tris-buffered saline/Tween-20 (TBS-T). After blocking in 5% normal goat serum (Vector Labs), sections were incubated with anti-phospho-p44/42 MAPK ERK1/2 rabbit monoclonal antibody (Thr202/Tyr204; diluted 1:200, Cell Signaling Technology, USA #4376) overnight at 4 °C or monoclonal rabbit IgG isotype control. Subsequently, biotinylated goat anti-rabbit IgG (1:100, Vector Labs) was applied for 30 min, before slides were incubated with ABC Elite Standard (Vector Labs) for 30 min. p-ERK1/2 was visualized by a 5-min incubation in DAB Reagent (Sigma) and subsequent hematoxylin counterstain. Slides were dehydrated, cleared in xylene and mounted with coverslips with Permount. Paraffin embedded colon cancer cells (SW48, carrying a p.Q56P mutation in MAP2K1) was used as positive control13. Normal bone from patients undergoing surgical resection for unrelated indications served as negative control (Fig. 4a).
Osteoblast mineralization and differentiation in vitro
Osteoblasts from affected and unaffected bone of patient Melo-18 were plated at passage 2 with 50,000 cells/well in 12-well plates and cultured to confluency in α-MEM supplemented with 10% FBS and antibiotics at 37 °C/8% CO2. Following confluence, osteoblasts were grown in osteoblast differentiation medium (50 µg/mL L-ascorbic acid, 10 nM dexamethasone, and 2.5 mM β-glycerophosphate), with or without 100 ng/mL recombinant BMP2 (#355-BM, R&D Systems, Minneapolis, MN), refreshing osteogenic media every 3 days for 7 weeks.
To visualize mineralization in osteoblast culture, cells were washed once with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. Fixed cells were washed three times with PBS and stained with 2% Alizarin Red S solution (pH 4.2) for 30 min at room temperature. Excess Alizarin Red S stain was removed with three distilled water washes. Cells were air-dried in the dark before imaging (Fig. 5e). During osteoblast mineralization in osteogenic medium, total RNA was collected at 2 weeks’ post-induction and used to examine gene expression by real-time quantitative PCR analysis.
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Freyschmidt, J. Melorheostosis: a review of 23 cases. Eur. Radiol. 11, 474–479 (2001).
Kotwal, A. & Clarke, B. L. Melorheostosis: a rare sclerosing bone dysplasia. Curr. Osteoporos. Rep. 15, 335–342 (2017).
Younge, D., Drummond, D., Herring, J. & Cruess, R. L. Melorheostosis in children. Clinical features and natural history. J. Bone Jt. Surg. Br. 61-B, 415–8 (1979).
Bostman, O. M., Holmstrom, T. & Riska, E. B. Osteosarcoma arising in a melorheostotic femur. A case report. J. Bone Jt. Surg. Am. 69, 1232–7 (1987).
Hellemans, J. et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat. Genet 36, 1213–8 (2004).
Mumm, S. et al. Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J. Bone Miner. Res. 22, 243–50 (2007).
Bonafe, L. et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am. J. Med Genet A 167A, 2869–92 (2015).
Whyte, M. P. et al. Melorheostosis: exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone 101, 145–155 (2017).
Fryns, J. P. Melorheostosis and somatic mosaicism. Am. J. Med. Genet. 1995, 199 (1995).
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–91 (2016).
Fischmann, T. O. et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 48, 2661–2674 (2009).
Marks, J. L. et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68, 5524–8 (2008).
Murugan, A. K., Dong, J., Xie, J. & Xing, M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8, 2122–4 (2009).
Waterfall, J. J. et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat. Genet. 46, 8–10 (2014).
Atkins, G. J. et al. RANKL expression is related to the differentiation state of human osteoblasts. J. Bone Miner. Res. 18, 1088–98 (2003).
Boyce, B. F. & Xing, L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 9(Suppl 1), S1 (2007).
Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).
Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–43 (2001).
Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet 68, 577–89 (2001).
Shore, E. M. & Kaplan, F. S. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone 43, 427–33 (2008).
Arcila, M. E. et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin. Cancer Res. 21, 1935–43 (2015).
Goyal, Y. et al. Divergent effects of intrinsically active MEK variants on developmental Ras signaling. Nat. Genet. 49, 465–469 (2017).
Rodriguez-Viciana, P. et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287–1290 (2006).
Schulz, A. L. et al. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin. Genet. 73, 62–70 (2008).
Couto, J. A. et al. Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am. J. Hum. Genet. 100, 546–554 (2017).
Chakraborty, R. et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124, 3007–15 (2014).
Estrada-Veras, J. I. et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 1, 357–366 (2017).
Ge, C., Xiao, G., Jiang, D. & Franceschi, R. T. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 176, 709–18 (2007).
Hoshi, K. et al. Histopathological characterization of melorheostosis. Orthopedics 24, 273–7 (2001).
de la Croix Ndong, J. et al. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. J. Bone Miner. Res. 30, 55–63 (2015).
Matsushita, T. et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell Biol. 29, 5843–57 (2009).
Arques, C. G., Doohan, R., Sharpe, J. & Torres, M. Cell tracing reveals a dorsoventral lineage restriction plane in the mouse limb bud mesenchyme. Development 134, 3713–22 (2007).
Hellemans, J. et al. Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis. Hum. Mutat. 27, 290 (2006).
Caunt, C. J., Sale, M. J., Smith, P. D. & Cook, S. J. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat. Rev. Cancer 15, 577–92 (2015).
Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–7 (2012).
Glorieux, F. H. et al. Normative data for iliac bone histomorphometry in growing children. Bone 26, 103–9 (2000).
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–5 (2012).
Robey, P. G. & Termine, J. D. Human-bone cells-invitro. Calcif. Tissue Int. 37, 453–460 (1985).
We thank Dr. William Gahl for early support of the study, Donna Butcher for assistance with immunohistochemistry, Daniela Gabriel, Petra Keplinger, Sonja Lueger and Phaedra Messmer for careful preparation of bone samples for histomorphometry. We are especially grateful to Kathleen Harper, the Melorheostosis Association, and the patients for their support of this study.
The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Kang, H., Jha, S., Deng, Z. et al. Somatic activating mutations in MAP2K1 cause melorheostosis. Nat Commun 9, 1390 (2018). https://doi.org/10.1038/s41467-018-03720-z
Journal of Experimental Medicine (2020)
Journal of Experimental Medicine (2020)
Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralization
Journal of Clinical Densitometry (2020)